Wells Fargo & Company Begins Coverage on AKCEA THERAPEUT (AKCA)

Wells Fargo & Company began coverage on shares of AKCEA THERAPEUT (NASDAQ:AKCA) in a research note published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $27.00 target price on the stock.

Several other equities research analysts have also recently issued reports on the company. Cowen and Company began coverage on AKCEA THERAPEUT in a report on Tuesday. They issued an outperform rating on the stock. Stifel Nicolaus began coverage on AKCEA THERAPEUT in a report on Tuesday. They issued a buy rating and a $19.00 price objective on the stock.

AKCEA THERAPEUT (AKCA) opened at 14.21 on Tuesday. AKCEA THERAPEUT has a 1-year low of $1.05 and a 1-year high of $16.30. The company’s market cap is $912.25 million. The stock has a 50 day moving average price of $10.80 and a 200-day moving average price of $10.80.

TRADEMARK VIOLATION WARNING: “Wells Fargo & Company Begins Coverage on AKCEA THERAPEUT (AKCA)” was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thestockobserver.com/2017/08/12/wells-fargo-company-begins-coverage-on-akcea-therapeut-akca.html.

In related news, major shareholder Ionis Pharmaceuticals Inc bought 3,125,000 shares of the stock in a transaction dated Wednesday, July 19th. The shares were acquired at an average cost of $8.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the insider now directly owns 28,884,540 shares in the company, valued at approximately $231,076,320. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

About AKCEA THERAPEUT

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Receive News & Ratings for AKCEA THERAPEUT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AKCEA THERAPEUT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply